Vitamin C

Clinical Summary

Vitamin C is a water-soluble essential nutrient. Humans lost L-gulonolactone oxidase ~60 million years ago, making dietary intake mandatory. It is an electron-donor cofactor for prolyl/lysyl hydroxylases (collagen), dopamine-β-hydroxylase (norepinephrine), γ-butyrobetaine hydroxylase (carnitine), HIF-prolyl hydroxylases (hypoxia response), and TET dioxygenases (5hmC DNA demethylation). A new covalent post-translational modification — vitcylation — was characterized in 2025 (PMID 40023152), adding direct lysine modification (e.g., STAT1 K298) to its mechanism catalog.

Where it delivers: scurvy prevention/reversal (universal), non-heme iron absorption (3–4× at 100–200 mg co-ingestion), collagen cross-linking (biochemistry-inevitable), cold-symptom duration reduction (8% adults / 14% children per Cochrane PMID 23440782), URI incidence in extreme physical stress (RR 0.48 in marathoners/soldiers), topical photoaging and hyperpigmentation (dermatology-grade evidence at 10–20% L-ascorbic acid, pH <3.5), and AMD progression slowing as part of the AREDS2 formulation.

Where the promise collapses: primary cardiovascular disease prevention (Cochrane null, PMID 28301692), cancer prevention (RCTs null), COVID-19 treatment (multiple 2023–2025 meta-analyses null), dementia prevention (observational only), and — most importantly — high-dose IV in sepsis, where LOVIT 2022 showed a signal for HARM (persistent organ dysfunction or death RR 1.21, PMID 35704292), ending the Marik "HAT protocol" era.

Dietary gap is real; mega-dosing is not necessary. The Linus Pauling Institute (Pauling's own institute) recommends 400 mg/day for healthy adults — an intellectually defensible midpoint between the RDA (75–90 mg, calibrated to scurvy prevention) and Pauling's historical 3–18 g/day (no longer defended by mainstream longevity voices). Plasma saturates at ~200 mg/day (PMID 8623000); oral bioavailability drops from ~70–90% below 200 mg to <50% above 1 g, bounded by SVCT1 transporter saturation (structure solved 2024, PMID 38956111). Oral–IV pharmacokinetic divergence (PMID 15068981) is the rationale for all pharmacologic-dose IV oncology trials.

Who benefits most: smokers (+35 mg/d), pregnant/lactating (+30–45 mg/d), picky-eater or low-fruit-diet adults, IBD patients (20–40% deficient per PMID 34222863, 36156920), alcohol use disorder, dialysis patients, and anyone supplementing iron for IDA. Who benefits least: healthy adults with ≥5 servings of fruit/vegetables daily.

Indications & Evidence

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal/primate→human | OA=Observational | NE=No evidence / contradicted BH: Bradford Hill criteria met (of 9). 7–9=strong | 5–6=moderate | 3–4=weak | 1–2=speculative Safety flags: -- no signals for this indication | MON monitor (known AEs, manageable) | WARN FAERS/trial safety signal — see Safety | AVOID contraindicated for this specific use Star ratings (volume): 5/5 multiple large RCTs + meta-analyses | 4/5 several human RCTs | 3/5 some human pilot / meta on surrogate | 2/5 animal/primate or very limited human | 1/5 no evidence or null

Prescribing

Dosing Table

Formulation Table

Divide ≥500 mg doses. Saturation of SVCT1 at the enterocyte caps single-dose uptake; 250 mg × 4 = superior tissue saturation vs single 1 g.

Condition-Specific Protocols

Acute URI (Common Cold) Protocol

Evidence: 5/5 treatment; 1/5 prevention (except extreme physical stress) | Key PMID 23440782, 38082300, 39803741, 33102597

Phase 1: Onset (first 24 h of symptoms)

• 500 mg every 4–6 h (total 1.5–2 g/d); continue food/fluids
• Add zinc lozenges within 24 h (separate evidence base; synergistic in community use)

Phase 2: Active illness

• Maintain 250–500 mg q6h until symptoms resolve
• Buffered form if GI irritated

Phase 3: Resolution

• Continue 500–1000 mg/d for 1–2 days after symptoms clear
• Return to maintenance 200–500 mg/d

Expected: ~8% shorter duration in adults, ~14% in children. Will NOT prevent future colds at these doses in the general population. Stop/reassess: if diarrhea develops, cut to divided 250 mg doses or switch to buffered form.

Iron Deficiency Anemia Protocol (Oral Repletion Adjunct)

Evidence: 5/5 mechanism / 3/5 modern comparative effectiveness | Key PMID 33136134

Phase 1: Take 100–200 mg vitamin C together with every iron dose (ferrous sulfate/succinate 30–65 mg elemental). Take on empty stomach if tolerated; with food if GI upset. Phase 2: Continue through ferritin repletion (~3–6 months for target ferritin ≥50 ng/mL). Phase 3: Maintain vitamin C baseline (RDA via diet) after iron targets met.

Expected: 3–4× non-heme iron absorption. Note 2020 JAMA Netw Open RCT (PMID 33136134) showed marginal added Hb benefit over ferrous succinate alone — most useful when iron source is plant-based or when doses are limited by GI tolerance. Stop/reassess: if HFE hemochromatosis, iron overload markers rising, or stones develop.

Athlete Protocol (Extreme Physical Stress)

Evidence: 4/5 URI prevention in this subgroup only | PMID 23440782

Pre-season / pre-event (2–4 wk): 250–500 mg/d Event day: 200–500 mg 2–3 h before exertion Post-event: resume baseline 200–500 mg/d

Caution (exercise adaptation): Do NOT routinely take >1 g immediately post-training in hypertrophy/strength phases. Modest blunting of training adaptations documented. See Community section.

AREDS2 Formulation (Intermediate or Late AMD in Fellow Eye)

Evidence: 4/5 as part of formula, not monotherapy | PMID 37702300, 39025435

• AREDS2 daily: 500 mg vitamin C + 400 IU vitamin E + 80 mg zinc + 2 mg copper + 10 mg lutein + 2 mg zeaxanthin
• Monitor: ophthalmology follow-up per AAO; no specific vitamin C lab tracking

IBD Repletion Protocol

Evidence: 4/5 for the deficiency (20–40% prevalence), 3/5 for outcomes | PMID 34222863, 36156920, 38467159

Active flare: 500–1000 mg/d buffered (sodium or calcium ascorbate) divided with food Remission: 250–500 mg/d standard or buffered Monitor: plasma vitamin C q3 mo active / q6–12 mo remission; check alongside iron, B12, folate, vitamin D

Safety

Interactions Table

Contraindications

• G6PD deficiency + IV HD (>5 g) — risk of oxidative hemolysis (canonical case PMID 30208815; 2024 cases PMID 38898838). Screen G6PD before any pharmacologic IV dosing.
• Severe renal impairment (GFR <30) — oxalate accumulation → kidney stones / oxalate nephropathy (PMID 38095544, 41856685). Limit to RDA only; reduce further if on dialysis except post-session 100–200 mg replacement.
• Calcium oxalate stone history — limit supplemental vitamin C to ≤1 g/d; prefer dietary sources. AUA guidance: avoid supplemental vitamin C in recurrent stone formers.
• Hemochromatosis (HFE C282Y/H63D) or iron overload — vitamin C enhances iron absorption AND mobilizes tissue iron; limit to RDA.
• High-dose IV in sepsis — LOVIT 2022 showed HARM signal (PMID 35704292); J-SSCG 2024 recommends against (PMID 39996161); SSC 2021 recommends against (PMID 34599691).

Adverse Effects

Common at supra-physiologic doses (>1 g/d oral):

• Osmotic diarrhea (10–20% at >2 g/d). Dose-dependent. Fix: divide doses, use buffered forms.
• Abdominal cramping, bloating (5–10%).
• Nausea (3–5% at >1 g, worse fasted).
• Heartburn/reflux — more with acidic ascorbic acid; use sodium/calcium ascorbate.

Uncommon/rare:

• Calcium oxalate kidney stones — chronic >2 g/d in males, stone-history patients, low fluid intake. 2 × risk at ≥1 g/d supplemental in men (Harvard cohorts). Dietary vitamin C does NOT show this signal.
• Oxalate nephropathy — IV HD or chronic >3 g/d oral with renal impairment (PMID 38095544; transplant case PMID 41856685).
• Hemolysis — IV HD with G6PD deficiency (PMID 38898838; canonical 30208815).
• Pseudohyperglycemia on GDH-PQQ glucose strips — can mimic DKA with IV HD.
• SJS/TEN-type reactions — very rare, case report for IV glutathione + vit cocktail (PMID 40057759); not a vitamin C-alone signal.

FAERS Signal Table (from BioMCP OpenFDA)

FAERS interpretation: Supplement/OTC ascorbic acid generates massive apparent signal (42,462 reports) dominated by bowel-prep (MoviPrep, Plenvu) and multivitamin co-reporting. Random-sample inspection of 2024+ reports found the suspect drug was typically oxybutynin, ruxolitinib, dupilumab, dimethyl fumarate, warfarin, tacrolimus, lenalidomide — not ascorbic acid. True suspect-drug vitamin C signals are concentrated in G6PD IV hemolysis, renal impairment + HD oral oxalate nephropathy, and dose-dependent GI intolerance. Everything else is background noise.

Monitoring Table

Special Populations

Renal Impairment

Hepatic Impairment

Pregnancy / Lactation

• Pregnancy: 85 mg RDA; up to 500 mg/d considered safe. In smokers, 500 mg/d may reduce preterm birth risk (PMID 40584396) and modify offspring asthma-associated epigenetic marks at age 5 (PMID 41044653).
• Lactation: 120 mg RDA; 200–500 mg/d safely maintains milk content. No adverse signal at ≤1 g/d.
• Preeclampsia: early observational signal not replicated in larger RCTs; do not supplement for this indication.

Synergies & Stacking

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

No CPIC or PharmGKB formal pharmacogenomic guideline for ascorbic acid exists as of 2026-04-17. All rows above are mechanism-informed or based on GWAS/case-series data, not clinical algorithms. G6PD screening before pharmacologic IV dosing is standard-of-care practice, not codified pharmacogenomics.

Community & Anecdotal Evidence

Disclaimer: Real-world user reports. Not clinical evidence. N-sizes estimated.

Dominant Sentiment

Polarized by dose tier. Topical vit C: strongly positive across r/SkincareAddiction, r/AsianBeauty (~thousands of threads). Oral low-dose: mildly positive, treated as a "base vitamin." Oral mega-dose and IV: polarized between orthomolecular evangelism (extremely positive) and medical skepticism (negative, especially post-LOVIT).

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• MLM involvement: LivOn Labs Lypo-Spheric aggressive ambassador marketing; "2× plasma" claim reposted everywhere.
• Influencer concentration: Orthomolecular lineage (Hoffer → Cathcart → Saul → Thomas Levy → Suzanne Humphries) is a coherent closed loop with Steve Hickey PhD; Mercola sells his own liposomal. Peter Attia explicitly does NOT take vitamin C. Huberman mentions it but it's not in his top 3. Rhonda Patrick cites 500 mg BID cognition studies as a positive but non-headline recommendation.
• Astroturfing signals: Suspiciously uniform 5-star reviews on liposomal products; cross-posting between health newsletters and product-affiliate pages.
• Commercial bias: IV clinic markups ($150–500/session × 10–50 sessions = $1,500–$25,000 out-of-pocket, no insurance). FTC action 2018 against Myers-cocktail marketer for deceptive claims.
• Beauty-industry capture (Japan/Korea): "Whitening" (bihaku 美白) IV culture rests on cultural colorism, not efficacy data.
• Carnivore "vit C unnecessary": Shawn Baker / early-carnivore Saladino claim rests on SVCT-glucose-competition theory — factually incorrect (SVCT2 is vit-C-specific, doesn't transport glucose). Paul Saladino's 2023 reversal to 300 g/d fruit carbs undercuts the position.
• Pauling halo: Two Nobel Prizes carried vitamin C megadose mythology well past its data. LPI (Pauling's own institute) has retreated to 400 mg/d.

Folk vs Clinical Reality Check

Aligned: topical vitamin C for skin (strong both ways); iron-absorption synergy (near-unanimous both); kidney-stone caution in men (community wary, RCT + cohort-confirmed); cold-duration modest benefit (both).

Diverged: IV mega-dose for cancer (community hopeful; Phase 2 pancreatic hint + mCRPC null + pending Phase 3 NCT06018883); IV for sepsis (community-driven Marik-HAT era reversed by LOVIT trial showing HARM — guideline bodies now recommend against); "immune boost" (community vastly overestimates; only extreme-physical-stress subgroup shows prevention); Pauling megadose (community still argues; clinical consensus abandoned); carnivore "no vit C needed" (fringe, scientifically incorrect SVCT claim).

The consistent pattern: community dosing is ~10× RDA; clinical evidence supports the LPI 400 mg/d midpoint as the efficiency plateau. Higher doses introduce kidney-stone and oxalate-nephropathy risk without clear outcome gain except in narrow specific protocols (AREDS2, IDA co-supplementation, acute URI treatment).

Deep Dive: Mechanisms & Research

Mechanisms with Clinical Translation

1. Hydroxylase cofactor (established). Prolyl/lysyl hydroxylases for collagen (PMID 18505499) — clinical translation: full (scurvy, wound healing, cofactor role universal).
2. Dopamine-β-hydroxylase cofactor — clinical translation: partial (norepinephrine synthesis disorders are rare; no routine clinical relevance).
3. γ-Butyrobetaine hydroxylase — carnitine synthesis; deficiency → fatigue (clinically relevant in severe depletion only).
4. HIF-prolyl hydroxylases (PHDs) — hypoxia response modulation; investigational role in cancer biology and ferroptosis (PMID 28366679).
5. TET DNA dioxygenases (5mC→5hmC). Vitamin C is a TET cofactor; documented in HSC differentiation, tumor antigen presentation (PMID 39388288), myeloid leukemia differentiation (PMID 41037397), and osteogenesis (PMID 41269246, 41402268). Clinical translation: active investigation — NCT07283900 (MDS), and TET2-guided vit C use is emerging in hematologic oncology.
6. Ferro-aging axis via ACSL4 inhibition (NEW 2026). Primate study (PMID 41819088, Cell Metab 2026) — oral vit C given to aged macaques for 40+ months inhibited ACSL4, reversed multi-omic aging clocks (epigenetic, transcriptomic, metabolomic), improved neurological and metabolic readouts. Paradigm-level mechanism. No human RCT.
7. Vitcylation PTM (NEW 2025). Direct covalent lysine modification (PMID 40023152, Cell 2025). STAT1 K298 vitcylation impairs TCPTP binding, sustains IFN signaling, enhances MHC-I expression and anti-tumor immunity. Fundamentally expands the pharmacodynamic model beyond reduction/cofactor.
8. Primate ovarian geroprotection (NEW 2025). 3.3-year macaque study (PMID 41092909, Cell Stem Cell 2025) — oral vit C reduced oocyte biological age by 1.35 years and somatic-cell age by 5.66 years via NRF2 pathway.
9. SVCT1 dimeric transport (cryo-EM 2024). PMID 38956111 — resolved intestinal absorption mechanism; explains dose-dependent saturation.
10. SVCT2 microglial ascorbate & AD (mouse 2025). PMID 40907096 — SVCT2-mediated microglial ascorbate uptake delays AD progression in mouse models.
11. Pharmacologic IV differential susceptibility. PMID 28366679 (Schoenfeld 2017) — O₂·⁻/H₂O₂-mediated selective kill of NSCLC and GBM cells (low catalase activity phenotype). Mechanistic basis for ongoing glioma / NSCLC / pancreatic trials.
12. Intergenerational endurance-inheritance (maternal). PMID 39921869 (Adv Sci 2025) — vit-C-dependent mechanism for maternal-exercise → offspring-performance transmission.

Clinical Trials (from BioMCP / ClinicalTrials.gov, selected)

Totals: 596 registered trials (condition=vitamin c); 308 COMPLETED; 51 RECRUITING; 56 WITH RESULTS POSTED.

Regulatory Status (from BioMCP)

• FDA: GRAS (21 CFR 182.3013, 182.3731, 182.3733). Prescription IV forms: Ascor (McGuff NDA209112, SUPPL-9 approved 2024-01-17); Fresenius Kabi generic ANDA217131 approved 2025-08-07. Oral combinations: MoviPrep (NDA021881), Plenvu (NDA209381). Infuvite Pediatric (NDA021265 SUPPL-44 2024-11-06). No boxed warnings.
• EMA: No centralized marketing authorization (national regulation as food supplement or well-established-use medicine). EFSA DRV: 110 mg/d PRI men, 95 mg/d PRI women.
• Japan: PMDA approves oral and IV products; J-SSCG 2024 now recommends AGAINST high-dose IV vit C in sepsis (GRADE 2B) — reversal from J-SSCG 2020 (PMID 39996161, 40087807).
• Guideline position summary:
  • Surviving Sepsis Campaign 2021: against (PMID 34599691).
  • SCCM Surviving Sepsis Campaign pediatric 2026: against high-dose adjunct (PMID 41869844).
  • ESPEN ICU 2023: RDA only, no routine pharmacologic dose (PMID 37517372).
  • AREDS2 (NEI): 500 mg as part of formula for AMD progression (PMID 37702300, 39025435).
  • ACR Gout 2020: neither for nor against (PMID 32391934, 32390306).
  • AUA stone prevention: avoid supplemental vit C in recurrent calcium stone formers.

Ataraxia Verdict (as of 2026-04-17)

Evidence Classification (Mode 5: Evidence Classifier)

Hype Check (Mode 1: Fallacy Radar)

• Appeal to authority: Linus Pauling's 2 Nobel Prizes granted disproportionate weight to his vit C megadose advocacy for decades after evidence failed.
• Hasty generalization: In vitro pharmacologic-dose pro-oxidant cancer kill → IV clinic marketing for "vitamin C cures cancer." Phase 3 evidence does not exist.
• Cherry-picking: Liposomal PK studies favoring the liposomal form are often manufacturer-funded. Independent replications are sparse.
• Appeal to popularity: "Everyone takes vitamin C" is the single most common rationalization; doesn't establish optimal dose.
• Correlation-causation reversal: Observational "high vit C intake low cancer/CVD" reverses in RCTs — likely confounded by healthy-user effect (fruit/vegetable intake).
• Anecdote as data: Marik's 47+47 before-after HAT retrospective (PMID 27940189) drove a decade of sepsis megadose enthusiasm that five large RCTs then reversed.
• Ad ignorantiam: "High-dose IV isn't proven harmful" — LOVIT 2022 now provides specific evidence of harm in sepsis.

Evidence Gaps

• No Phase 3 data on oral HD (>1 g/d) for longevity or cancer prevention in humans — everything new is bench/primate.
• No Cochrane refresh on vit C + common cold since 2013 — Hemilä 2025 (PMID 39803741) is narrative, not a formal update.
• Vitcylation (PMID 40023152) described 2025 but no clinical outcome trials yet.
• Primate longevity findings (PMID 41819088, 41092909) not yet translated to human RCTs.
• TET2-guided vitamin C in hematologic oncology is investigational only.
• No formal CPIC/PharmGKB pharmacogenomic guideline exists for any SNP × vit C interaction.
• FAERS suspect-only filter behaves erratically on OpenFDA for ascorbic acid; accurate signal-attribution requires manual review.
• East Asian trial registries (J-STAGE, KoreaMed, CNKI) not comprehensively mined; likely underrepresentation of Asian ICU and topical-melasma data.

Bias Flags (Mode 4: First Principles)

• What survives scrutiny: deficiency treatment, iron absorption synergy, collagen cofactor role, 8–14% cold-duration reduction, URI prevention in extreme-physical-stress subgroup, topical dermatologic benefit, AMD progression slowing as part of AREDS2.
• What fails scrutiny: HD IV sepsis (harmed), HD IV COVID (null), CVD primary prevention (null), cancer primary prevention (null), dementia prevention (observational only), blood-pressure effect (trivial), T2DM glycemic control (inconsistent).
• Fragile claims: liposomal bioavailability premium (modestly higher PK, no clinical-outcome superiority demonstrated); ester-C (no superiority); "bowel tolerance" Cathcart protocol (clinically unvalidated).
• Well-established mechanisms with thin clinical translation: hypoxia-response (HIF), epigenetic (TET), ferroptosis modulation, vitcylation PTM — exciting preclinical biology, not yet clinical.

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing patterns detected:
  • Liposomal premium pricing ($30–60/mo vs $5–10/mo standard) with manufacturer-funded PK studies; clinical-outcome superiority unproven.
  • "Ester-C" proprietary branding with no demonstrated advantage over generic calcium ascorbate.
  • IV clinic markups ($150–500/session × 10–50 sessions).
  • "Immune boost" framing across entire supplement-industry marketing despite Cochrane showing no prevention effect in general population.
• Influencer economics:
  • LivOn Labs Lypo-Spheric: aggressive ambassador program; repeated "2× plasma level" claim across biohacker Substacks/newsletters.
  • Mercola: sells own liposomal product while publishing "doctors hide this" content — vertical-integration conflict.
  • Orthomolecular lineage (Hoffer → Cathcart → Saul → Thomas Levy → Humphries → Hickey): coherent closed-loop advocacy with anti-pharma framing; single ideological home at orthomolecular.org.
  • Riordan Clinic (40,000+ IV treatments) monetizes advanced-cancer patients.
  • Beauty-industry capture in Japan/Korea: "whitening" (bihaku) IV culture monetizes colorism.
• Counter-narrative manipulation: Pharma fearmongering is minimal here — no patented competing product whose interests would be served by vit C fear. This makes pro-supplement cui bono dominant.
• Cui bono summary: Pro-supplement actors ($1+ billion global market, IV clinics, orthomolecular practitioners, liposomal manufacturers) vastly outweigh anti-supplement actors. Consumer risk: overpaying for marginal PK gains; investing in IV protocols with weak evidence; neglecting dietary fruit/vegetable intake in favor of pills.
• Red team highlight: The strongest argument AGAINST supplemental vit C beyond RDA in healthy people is the reversal-of-effect pattern (observational positive → RCT null) combined with small but real oxalate-stone risk in males at chronic >1 g/d. The most concerning angle is the orthomolecular lineage's continued advocacy for HD IV in sepsis despite LOVIT harm data — a pattern of ideology-over-evidence.

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 7/10. High utility for specific indications (IDA adjunct, URI treatment, scurvy, topical dermatology, AREDS2, IBD repletion) and broad dietary adequacy insurance. Deducted points: many heavily promoted indications (cancer, sepsis, CVD, COVID) are null or harmful; risk of overuse without benefit.
• Opportunity cost: Very low. $5–10/month standard ascorbic acid. Minimal complexity. Reversible. No withdrawal.
• Verdict: ADD (low dose) for healthy adults without reliable fruit/vegetable intake; otherwise CONDITIONAL.
• Conditions (if conditional):
  • Reliable dietary intake (≥5 servings F/V daily): diet alone is sufficient; supplement unnecessary.
  • Smoker / alcohol use / picky eater / IBD / dialysis / elderly: ADD 200–500 mg/d.
  • Acute URI onset: 1–2 g/d divided, limited duration.
  • Iron deficiency anemia on iron supplementation: 100–200 mg with each iron dose.
  • Pregnancy (smoking): 500 mg/d for preterm-birth risk reduction.
  • Male with calcium oxalate stone history: DO NOT supplement >RDA; dietary sources only.
  • Active chemotherapy: avoid >500 mg/d without oncologist consultation.
  • Septic ICU patient: AGAINST pharmacologic IV dose (guideline-backed).
  • Hemochromatosis / HFE carrier: RDA only; avoid chronic HD.
  • Photoaging / melasma: topical 10–20% AA pH <3.5 is the evidence-backed route; oral role minimal for skin.

Bottom Line

Vitamin C is one of the best-characterized nutrients in medicine — and most of its real clinical value lies at the low end of the dose curve (200–500 mg/d oral), not at the pharmacologic end that supplement marketing, IV clinics, and orthomolecular evangelists have built an industry around. The 2022 LOVIT trial's HARM signal in sepsis closed a decade-long chapter of Marik-HAT enthusiasm; J-SSCG 2024's reversal to "against" cements that. The exciting 2025–2026 mechanism papers (vitcylation, ferro-aging in primates, ovarian geroprotection, TET2-guided oncology) expand the biology without yet creating actionable human dosing changes. Take it if your diet is thin on fruit and vegetables, if you're treating an acute URI, if you're supplementing iron, if you smoke, or if you're deficient. Don't take mega-doses for cancer, CVD, COVID, or longevity without a trial protocol. Topical is where the skin payoff lives.

Practical Notes

Brands & Product Selection

Third-party testing (USP Verified, NSF Certified, ConsumerLab Approved) preferred. Examples with documented quality: NOW Foods (budget, USP), Thorne Research (pharmaceutical grade, NSF), Pure Encapsulations (hypoallergenic, HCP-grade), Life Extension, Seeking Health, Jarrow, Solgar, Doctor's Best. Liposomal specialists: LivOn Labs (most-studied brand; PK data), Seeking Health, Mercola (vertical-integration conflict disclosed). Topical benchmark: Skinceuticals CE Ferulic (15% L-AA + 1% α-tocopherol + 0.5% ferulic acid, pH 2.5–3.5); alternates: Timeless 20% C+E+Ferulic, Paula's Choice C15 Super Booster, Drunk Elephant C-Firma. Melano CC (Rohto, Japan), Klairs Freshly Juiced (Korea), By Wishtrend Pure Vit C 21.5 for hyperpigmentation. Red flags: proprietary blends hiding amounts, Pinterest-perfect before/after marketing, $90+ "nano" supplements without PK data, "cures cancer" claims, IV clinics without physician oversight.

Storage & Handling

Room temperature 15–25°C. Amber/opaque containers — light degrades vitamin C. Dry — moisture accelerates oxidation. Tablets/capsules: 2–3 yr unopened, 12–18 mo after opening. Liquid liposomal: 6–12 mo; refrigerate post-opening. Topical red flag: if your vitamin C serum has turned orange/brown/amber, it's oxidized and inactive — discard.

Palatability & Compliance

Ascorbic acid powder is tart-sour — mixes well in orange juice, smoothies, lemon water. Buffered forms nearly tasteless. Chewable tablets can erode enamel (rinse mouth after). Effervescent tablets pleasant-tasting and absorb well. Liposomal liquid often described as "pond water / mushroom-forward" — take in a shot with chaser. Compliance driver: if you are going to take it, divide the dose to align with meals you already eat, rather than creating new reminders.

Exercise & Circadian Timing

Exercise: DO NOT routinely take >1 g immediately post-training if optimizing hypertrophy or strength adaptations — modest blunting of training signaling has been reported (Stronger By Science consensus; physiological rationale via ROS-signaling damping). Pre-workout 250–500 mg may reduce exercise-induced oxidative stress in specific contexts. Circadian: no effect on sleep at maintenance dose; mega-dose (>3 g) occasionally reported as mildly stimulating or increasing nocturnal urinary frequency — avoid at bedtime.

Reference Ranges (Expected Biomarker Changes)

Cost

• Ascorbic acid powder: $0.15/day at 500 mg → $4.50/month → $54/year
• Ascorbic acid tablets: $0.25/day → $7.50/month
• Sodium ascorbate: $0.35/day → $10.50/month
• Calcium ascorbate: $0.40/day → $12/month
• Liposomal liquid (1 g): $1.50/day → $45/month → $540/year
• Ester-C (branded): $0.80/day → $24/month
• IV Ascor prescription: typically $100–300/session in integrative clinics
• Riordan/alt-oncology IV: $150–500/session × 10–50 sessions = $1,500–$25,000 out-of-pocket

Standard ascorbic acid powder = best value. Liposomal premium justified only if consistently dosing >1 g/d or GI-intolerant. Ester-C marketing exceeds evidence — prefer generic calcium ascorbate at lower cost.

What We Don't Know

• Whether primate ferro-aging findings (PMID 41819088) translate to human longevity outcomes — requires decade-scale human RCTs that are unlikely to run.
• Whether vitcylation-modified STAT1 K298 is clinically exploitable in human cancer immunotherapy.
• Whether TET2-guided vitamin C in hematologic oncology (trials NCT07283900, PMID 41037397) will show outcome benefit.
• Phase 3 outcomes for HD IV in pancreatic cancer (NCT06018883, expected 2026-08).
• Whether the LOVIT harm signal in sepsis generalizes to all critical illness or is sepsis-specific; LOVIT subtype analysis (PMID 39774855) hints subgroups may respond differently.
• Whether oral megadose in COVID ambulatory care has a real small-effect signal (Hemilä reanalysis PMID 34040614 suggested so) that population-level RCTs underpowered.
• Optimal supplemental dose for pregnant smokers (500 mg/d is the preterm-birth signal, not a finalized RDA).
• Clinical relevance of SLC23A1/A2 polymorphisms — GWAS associations exist; dose-adjustment algorithms do not.
• Whether any liposomal formulation delivers superior clinical outcomes beyond superior PK.
• The exact threshold at which chronic vit C dose starts meaningfully increasing oxalate nephrolithiasis risk in non-stone-prone populations.
• Why non-US post-op AF trials show stronger effects than US trials (PMID 28143406).
• Whether emerging mechanisms (ACSL4, SVCT2 microglial AD, intergenerational endurance inheritance) will matter clinically.

References

Cochrane Systematic Reviews / Major Meta-analyses

• Hemilä H, Chalker E. 2013. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. PMID 23440782. — 29 RCTs, N=11,306. Adults −8%, children −14% duration; general-population prevention null; RR 0.48 extreme-physical-stress subgroup.
• Hemilä H, Louhiala P. 2013. Vitamin C for preventing and treating pneumonia. Cochrane. PMID 23925826.
• Bjelakovic G et al. 2012. Antioxidant supplements for prevention of mortality. Cochrane. PMID 18425980.
• Wilkinson M et al. 2014. Vitamins C and E for asthma and exercise-induced bronchoconstriction. Cochrane. PMID 24936673.
• Evans JR, Lawrenson JG. 2023. Antioxidant vitamin and mineral supplements for slowing progression of AMD. Cochrane. PMID 37702300.
• Al-Khudairy L et al. 2017. Vitamin C supplementation for primary prevention of cardiovascular disease. Cochrane. PMID 28301692.
• Langer G et al. 2024. Cochrane nutritional interventions for pressure ulcers. PMID 38345088.
• Hemilä H, Chalker E. 2019. Vitamin C reduces ICU length of stay meta-analysis. PMID 30934660.
• Hemilä H, Chalker E. 2020. Vitamin C reduces mechanical ventilation duration. PMID 32047636.
• Hemilä H, Suonsyrjä T. 2017. Vitamin C for post-op AF meta-analysis. PMID 28143406.
• Hemilä H, Chalker E. 2023. Vitamin C reduces cold severity meta-analysis. BMC Public Health. PMID 38082300.
• Hemilä H, Chalker E. 2025. Cold & pneumonia update. Pol Arch Intern Med. PMID 39803741.
• Hemilä H, Carr A. 2021. Common cold reanalysis — 70% recovery signal. PMID 34040614.
• Juraschek SP et al. 2012. Vitamin C on blood pressure meta-analysis. PMID 22492364.
• Juraschek SP et al. 2011. Vitamin C on serum uric acid meta-analysis. PMID 21671418.
• Ashor AW et al. 2014. Endothelial function meta-analysis (44 RCTs). Atherosclerosis. PMID 24792921.
• Ashor AW et al. 2015. Vit C + E endothelial. Br J Nutr. PMID 25919436.
• Fujii T et al. 2022. Sepsis adjunctive NMA. PMID 34750650.
• Zeng et al. 2023. HD IV vit C sepsis meta-analysis. PMID 37861551.
• Xu et al. 2023. Oral/IV vit C critical illness mortality. PMID 37111066.
• Kow et al. 2023. Vit C in COVID-19 RCT meta. PMID 37071316.
• Rawat D et al. 2021. Vit C + COVID-19 meta. PMID 34739908.
• Xu 2024. COVID vit C meta (benefit on hospitalization, no mortality). PMID 39421622.
• Zhou 2025. COVID vit C meta (no benefit). PMID 41174501.
• Ran L et al. 2020. Common cold severity meta-analysis (10 RCTs). PMID 33102597.
• Carr AC. 2025. Liposomal vit C scoping review. PMID 40506693.
• Calder 2025. Enhanced delivery forms SLR. PMID 39861409.
• Sharma 2024. Vit C in community-acquired pneumonia TSA. PMID 38783029.
• Alangari 2026. HD IV vit C benefits/risks SR. PMID 41815850.
• Pereira 2025. Preterm birth meta-analysis. PMID 40584396.
• Bird 2024. Obesity-adjusted vit C requirements SR. PMID 38666038.
• Lampousi A-M et al. 2024. Vit C, E, β-carotene & T2DM meta-analysis. Adv Nutr. PMID 38493875.
• Sarkar 2025. Antioxidants in melasma SR. PMID 40487500.
• Wang 2024. Micronutrients & androgenetic alopecia SR. PMID 39440586.
• Rozemeijer 2023. Pre-op vit C & peri-procedural myocardial injury. PMID 37735625.
• Li 2020. Vit C + iron in IDA (JAMA Netw Open). PMID 33136134.
• Qi 2024. Hypertension NMA (vit B2/C/D/E/folate). PMID 38296289.
• Mohseni 2022. Vit C + E on cancer survival. PMID 36136247.

Landmark Clinical Trials

• Fowler AA 3rd et al. 2019. CITRIS-ALI. PMID 31573637.
• Fujii T et al. 2020. VITAMINS. PMID 31950979.
• Moskowitz A et al. 2020. ACTS. PMID 32809003.
• Sevransky JE et al. 2021. VICTAS. PMID 33620405; long-term 36853612.
• Lamontagne F et al. 2022. LOVIT (HARM signal). PMID 35704292.
• Adhikari NKJ et al. 2023. LOVIT-COVID / REMAP-CAP harmonized (futility). PMID 37877585.
• Fujii T. 2025. Sepsis paradox synthesis. PMID 41613893.
• Rynne et al. 2025. LOVIT sepsis-subtype substudy. PMID 39774855.
• Vandervelden et al. 2025. C-EASIE trial (neg primary, positive SOFA≥6 subgroup). PMID 40269974.
• Müller et al. 2025. LOVIT platelet post-hoc (null). PMID 40927646.
• Segall 2026. US IV vit C utilization trends. PMID 41452227.
• Marik P et al. 2017. HAT retrospective (methodologically flawed). PMID 27940189.
• Padayatty SJ et al. 2004. Oral-IV PK divergence. PMID 15068981.
• Padayatty SJ et al. 2003. Vit C antioxidant review. PMID 12569111.
• Levine M et al. 1996. PNAS PK study (RDA basis). PMID 8623000.
• Graumlich JF et al. 1997. Three-compartment PK model. PMID 9327438.
• Dunleavy KA et al. 2021. IBD vit C deficiency case series. PMID 34222863.
• Gordon BL et al. 2022. IBD vit C deficiency prevalence (N=172). PMID 36156920.
• Ma Y et al. 2014. Ovarian cancer IV C + chemo. PMID 24500406.
• Bodeker 2024. Pancreatic cancer RCT (gem/nab-pac + HD AA). PMID 39369582.
• Paller 2024. mCRPC Phase II IV AA + docetaxel (NEGATIVE). PMID 39076107.
• Jameson 2025. mPDAC Phase IB HD AA + chemo. PMID 41197185.
• Hoffer LJ et al. 2015. HD IV AA + cytotoxic chemo Ph I/II. PMID 25848948.
• Schoenfeld JD et al. 2017. O₂·⁻/H₂O₂ selective cancer mechanism. Cancer Cell. PMID 28366679.
• Łukawski M et al. 2020. Liposomal PK. PMID 31264495.
• Gopi S, Balakrishnan P. 2021. Liposomal vs non-liposomal clinical PK. PMID 32901526.
• Davis JL et al. 2016. Liposomal delivery PK. PMID 27375360.
• Cathcart RF. 1981. Bowel tolerance protocol. PMID 7321921.
• Žmitek K et al. 2024. Collagen + vit C skin density RCT. PMID 38931263.
• Haque R et al. 2024. Vit C vs surgical gingival depigmentation RCT. PMID 39781402.
• Li et al. 2025. Vitamin intake & kidney stones. Medicine. PMID 41430982.

Mechanism / Emerging Biology (2024–2026)

• Liu et al. 2026. Ferro-aging / ACSL4 in primates. Cell Metab. PMID 41819088.
• Jing et al. 2025. Primate ovary geroprotection via NRF2. Cell Stem Cell. PMID 41092909.
• He et al. 2025. Vitcylation — new PTM, STAT1 K298. Cell. PMID 40023152.
• Thaler et al. 2026. Vit C & epigenetic osteogenesis. JBMR. PMID 41269246.
• Ho et al. 2025. TRIM37-PARP1-TET1-5hmC in osteoporosis. Nat Commun. PMID 41402268.
• Cheng et al. 2024. TET2 + vit C tumor antigen presentation. JCI Insight. PMID 39388288.
• Leesang et al. 2025. ATRA + ascorbate TET2 synergy in myeloid leukemia. Cell Rep. PMID 41037397.
• Kobayashi et al. 2024. SVCT1 dimeric cryo-EM. Nat Commun. PMID 38956111.
• Portugal et al. 2025. SVCT2 microglia & AD onset. Redox Biol. PMID 40907096.
• Shi et al. 2025. Vit-C-dependent intergenerational endurance inheritance. Adv Sci. PMID 39921869.
• Shorey-Kendrick 2025. Prenatal vit C + offspring asthma CpGs at age 5. Clin Epigenetics. PMID 41044653.
• Lykkesfeldt 2025. Authoritative pharmacology of vitamin C. Pharmacol Rev. PMID 39986139.
• Boyera et al. 1998. Collagen synthesis by fibroblasts. PMID 18505499.

Safety & Regulatory

• Wang et al. 2024. Hemolysis with HD IV vit C (G6PD-relevant). PMID 38898838.
• Rees et al. 2018. Massive oxidative hemolysis + renal failure in G6PD (canonical). PMID 30208815.
• Llanos et al. 2024. Oxalate nephropathy clinical/pathology. Kidney360. PMID 38095544.
• Rodrigues 2026. Oxalate nephropathy in kidney transplant. BMJ Case Rep. PMID 41856685.
• Hemilä H. 2024. Vit C deficiency → pulmonary hypertension case-report SR. PMID 38504249.
• Evans L et al. 2021. Surviving Sepsis Campaign 2021. Intensive Care Med. PMID 34599691.
• Shime N et al. 2025. J-SSCG 2024 Japanese sepsis guideline (against HD vit C). Acute Med Surg. PMID 39996161; J Intensive Care. PMID 40087807.
• Weiss SL et al. 2026. Surviving Sepsis Campaign pediatric 2026. PMID 41869844.
• Singer P, Blaser AR, Berger MM et al. 2023. ESPEN ICU guideline. PMID 37517372.
• FitzGerald JD et al. 2020. ACR Gout guideline. PMID 32391934.
• Abdullah M et al. 2023. Vitamin C. StatPearls. PMID 29763052.
• Keenan TD et al. 2025. AREDS2 follow-up. Ophthalmology. PMID 39025435.
• Zhou 2025. Serum vit C & AD mortality (NHANES). PMID 39531360.
• NIH Office of Dietary Supplements — Vitamin C Health Professional Fact Sheet.
• EFSA Panel on Dietetic Products, Nutrition and Allergies. 2013. Dietary Reference Values for vitamin C.

Additional Resources

• Linus Pauling Institute Micronutrient Information Center — Vitamin C.
• Examine.com — Vitamin C evidence summary.